HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Extract Full Text (PDF) All Versions of this Article: dc06-2595v1 30/6/1611    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by González, G. C. Articles by Pérez, A. Search for Related Content PubMed PubMed Citation Articles by González, G. C. Articles by Pérez, A. Social Bookmarking                What's this?

Thyroid Autoimmunity at Onset of Type 1 Diabetes as a Predictor of Thyroid Dysfunction

¹ Pediatric Department, Hospital Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
² Endocrinology Department, Hospital Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
³ Biochemical Department, Hospital Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

Address correspondence and reprint requests to Gemma Carreras González, Hospital Sant Pau, Pediatric Department, Sant Antoni M Claret 167, 08025 Barcelona, Spain. E-mail: gcarreras{at}santpau.es

Abbreviations: AITD, autoimmune thyroid disease • TG-Ab, tyroglobulin autoantibody • TPO-Ab, thyroperoxidase autoantibody • TSH, thyrotropin

	INTRODUCTION

TOP INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

 
Type 1 diabetes and autoimmune thyroid diseases (AITDs) often coexist in the same individual and in the same family. In the general population, AITD is more frequent in female subjects and prevalence increases with age. In diabetic patients, age and sex distributions are similar, but the prevalence is higher and increases with duration of the disease (1–3,4). Thyroid dysfunction can affect metabolic control in type 1 diabetes, and some studies (3) have shown a higher severity of diabetes when it is associated with AITD, although other studies (4) did not find these differences. Nevertheless, there is general agreement (5,6) on the utility of systematic screening of AITD in the type 1 diabetes population given its high prevalence, but procedure and frequency remain controversial. The aim of the present study was to determine the presence of thyroid autoantibodies at type 1 diabetes onset and its predictive capacity for the future development of thyroid dysfunction.

	RESEARCH DESIGN AND METHODS—

TOP INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

 
Between September 1987 and January 1994, 204 patients were consecutively diagnosed with type 1 diabetes at our institution. One patient had developed primary hypothyroidism 3 years before the development of type 1 diabetes, 10 patients were not followed up after a few months from diagnosis, and thyroid autoimmunity at diagnosis was not determined in 17 patients. The remaining 176 patients were included in the study. The mean age at diabetes diagnosis was 24.4 ± 9.4 years, 65% were male subjects, and the percentage of islet cell antibody positivity was 76%. The mean follow-up was 9.6 ± 4.3 years. Thyroid autoimmunity was determined at onset by hemagglutination, measuring thyroperoxidase autoantibodies (TPO-Abs) and tyroglobulin autoantibodies (Tg-Abs), and were considered positive at a dilution of 1/100. All patients underwent clinical follow-up, and thyrotropin (TSH) was monitored every 1–2 years using a commercial noncompetitive immunoassay. Thyroid dysfunction was diagnosed in the presence of a serum TSH alteration (normal range 0.3–5 mUI/l) with or without symptoms. Statistical analysis was performed with SPSS version 14.0 for Windows using ² and Student's t tests. Data are expressed as means ± SE. Statistical significance was established at P < 0.05.

	RESULTS—

TOP INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

 
Twenty-five of 176 patients (14.2%) were TPO-Ab positive at type 1 diabetes diagnosis. Eighteen of these 25 patients developed thyroid dysfunction at follow-up (primary hypothyroidism, defined as TSH >5 mUI/l in 17 cases and hyperthyroidism in 1 case). Only 1 of the 151 negative subjects at type 1 diabetes diagnosis developed hypothyroidism; he was a 14-year-old subject at type 1 diabetes onset who later turned TPO-Ab positive and developed hypothyroidism 15 years after diabetes diagnosis. Tg-Abs were less sensitive than TPO-Abs, being negative in 8 of 18 patients who developed hypothyroidism. The mean time to thyroid dysfunction development from type 1 diabetes onset was 8.1 ± 4.2 years. Interestingly, the seven TPO-Ab–positive patients who maintained normal thyroid function after 8.0 ± 5.0 years of follow-up were younger at type 1 diabetes onset than the patients who developed thyroid dysfunction (20.1 ± 6.2 vs. 29.5 ± 11.8 years; P < 0.05). Furthermore, patients who developed thyroid dysfunction were older at type 1 diabetes diagnosis than those who did not (28.7 ± 12 vs. 23.9 ± 8.9 years; P < 0.05). As expected, there were also sex differences, with thyroid dysfunction more frequent in female subjects than in male subjects (11 of 61 [18.3%] and 8 of 114 [7.0], respectively; P < 0.05)

Table 1 shows the prevalence of thyroid dysfunction according to the presence of TPO-Abs at type 1 diabetes onset. Further data analysis showed that the presence of TPO-Abs at type 1 diabetes onset can predict the development of thyroid dysfunction with 95% sensitivity (18 of 19 cases of future thyroid dysfunction were detected), 96% specificity (150 of 157 patients were correctly classified as normal), a 99% negative predictive value (only 1 of 151 patients classified as normal later developed thyroid dysfunction), and 72% positive predictive value (7 of 25 patients remained normal in the follow-up).

	CONCLUSIONS—

TOP INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

Although there is general agreement that the high prevalence of thyroid dysfunction in type 1 diabetes subjects justifies screening in all patients (5,6), it is not clear which is the best procedure and how often to perform it. The American Diabetes Association (7) and several authors (8,9) recommend annual screening for thyroid disease in all type 1 diabetes subjects with TSH measurement; this procedure is considered the most sensitive way to identify patients with thyroid dysfunction, as autoantibodies may persist for many years without thyroid dysfunction. However, the American Diabetes Association recommendations note that the presence of thyroid autoantibodies increase the risk for thyroid disease, and Hansen et al. (8) did not find any initial TPO-Ab–negative patients who developed thyroid disease after 3 years of follow-up. Other authors (10,11) recommend screening using TSH and TPO-Abs. In a cohort of 58 type 1 diabetic patients enrolled in the Diabetes Control and Complications Trial and followed for 18 years, Umpierrez et al. (10) observed that TPO-Ab–positive subjects were 17.9 times more likely to develop thyroid dysfunction. These authors recommended annual screening using TSH determination, particularly in patients with positive TPO-Abs. Barker (11) screened type 1 diabetic patients with TPO-Abs and thyroid function at onset and every 1–2 years thereafter and patients with positive TPO-Abs every 6–12 months. Finally, a third group of authors (1,12) recommends TSH determination only in TPO-Ab–positive patients. In our study, the high sensitivity and especially the high negative predictive value of TPO-Abs for the development of thyroid dysfunction over a mean follow-up of 9.6 years support a screening strategy with determination of TPO-Abs in all type 1 diabetic subjects at diagnosis. In agreement with previous studies (8,13), Tg-Abs were less sensitive and did not increase TPO-Ab–positive predictive value. Thereafter, an annual TSH determination would be performed only in subjects with positive autoantibodies. Using this procedure, only one case of hypothyroidism was missed, appearing 15 years after the onset of diabetes in a patient who was a 14-year-old at diabetes onset and who was later TPO-Ab positive.

Considering that the prevalence of TPO-Ab positivity may increase with time (1,3,8), further studies are required to investigate if additional determination of TPO-Abs after diagnosis may be useful, specially in younger patients.

	Acknowledgments

 
This study was funded by Grants ISCIII-RETIC RD06, PI052099 and PI051540 from the Fondo de Investigación Sanitaria, Carlos III Health Institute, Spain.

	Footnotes

 
Published ahead of print at http://care.diabetesjournals.org on 19 March 2007. DOI: 10.2337/dc06-2595.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

Received for publication December 22, 2006. Accepted for publication March 12, 2007.

	References

TOP INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

 

1. Kordonouri O, Klinghammer A, Lang EB, Grüters-Kieslich A, Grabert M, Holl RW: Thyroid autoimmunity in children and adolescent with type 1 diabetes. Diabetes Care 25:1346–1350, 2002[Abstract/Free Full Text]
   
2. Kordonouri O, Hartmann R, Deiss D, Wilms M, Grüters-Kieslich A: Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration and puberty. Arch Dis Child 90:411–414, 2005[Abstract/Free Full Text]
   
3. Franzese A, Buono P, Mascolo M, Leo AL, Valerio G: Thyroid autoimmunity starting during the course of type 1 diabetes denotes a subgroup of children with more severe diabetes. Diabetes Care 23:1201–1202, 2000[Free Full Text]
   
4. Fernández-Castáner M, Molina A, López-Jiménez L, Gómez JM, Soler J: Clinical presentation and early course of type 1 diabetes in patients with and without thyroid autoimmunity. Diabetes Care 22:377–381, 1999[Abstract]
   
5. Jaeger C, Hatziagelaki E, Petzoldt R, Bretzel RG: Comparative analysis of organ-specific autoantibodies and celiac disease-associated antibodies in type 1 diabetic patients, their first-degree relatives, and healthy control subjects. Diabetes Care 24:27–32, 2001[Abstract/Free Full Text]
   
6. Glastras SJ, Craig ME, Verge CF, Chan AK, Cusumano JM, Donaghue KC: The role of autoimmunity at diagnosis of type 1 diabetes in the development of thyroid and celiac disease and microvascular complications. Diabetes Care 28:2170–2175, 2005[Abstract/Free Full Text]
   
7. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, Deeb L, Grey M, Anderson B, Holzneister LA, and Clark N: ADA statement. Care of children and adolescents with type 1 diabetes. Diabetes Care 28:186–212, 2005[Free Full Text]
   
8. Hansen D, Bennedbaek FN, Hoier-Madsen M, Hegedüs L, Jacobsen BB: A prospective study of thyroid dysfunction, morphology and autoimmunity in young patients with type 1 diabetes. Eur J Endocrinol 148:245–251, 2003[Abstract]
   
9. Hoffman RP: Thyroid stimulating hormone screening is more sensitive for detecting thyroid abnormalities in children and adolescents with type 1 diabetes (Letter). Diabetes Care 26:255, 2003[Free Full Text]
   
10. Umpierrez GE, Latif KA, Murphy MB, Lambeth HC, Stentz F, Bush A, Kitabchi A: Thyroid dysfunction in patients with type 1 diabetes. Diabetes Care 26:1181–1185, 2003[Abstract/Free Full Text]
    
11. Baker JM: Clinical review: type 1 diabetes-associated autoimmunity: natural history, genetic associations and screening. J Clin Endocrinol Metab 91:1210–1217, 2006[Abstract/Free Full Text]
    
12. Maugendre D, Guilhem I, Karacatsanis C, Poirier JY, Leguerrier AM, Lorcy Y, Derrien C, Sonnet E, Massart C: Anti-TPO antibodies and screening of thyroid dysfunction in type 1 diabetic patients. Ann Endocrinol (Paris) 61:524–530, 2000 [Article in French][Medline]
    
13. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE: Serum TSH, T₄, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489–499, 2002[Abstract/Free Full Text]
    

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				R. E. Warren and B. M. Frier Thyroid Autoimmunity at Onset of Type 1 Diabetes as a Predictor of Thyroid Dysfunction: Response to Gonzalez et al. Diabetes Care, November 1, 2007; 30(11): e120 - e120. [Full Text] [PDF]

				G. Carreras-Gonzalez and A. Perez Thyroid Autoimmunity at Onset of Type 1 Diabetes as a Predictor of Thyroid Dysfunction: Response to Warren and Frier Diabetes Care, November 1, 2007; 30(11): e121 - e121. [Full Text] [PDF]

This Article Extract Full Text (PDF) All Versions of this Article: dc06-2595v1 30/6/1611    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by González, G. C. Articles by Pérez, A. Search for Related Content PubMed PubMed Citation Articles by González, G. C. Articles by Pérez, A. Social Bookmarking                What's this?